Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T 2 DM : Insights From a Systematic Review and Meta‐Analysis
Open Access
- 12 May 2026
- journal article
- review article
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (3) , e70238
Abstract
Background: Type 2 diabetes mellitus (T2DM) often requires combination therapy when metformin alone becomes insufficient. Empagliflozin (SGLT2 inhibitor) and sitagliptin (DPP‐4 inhibitor) are commonly used add‐on agents with differing metabolic profiles. This systematic review and meta‐analysis compared their glycaemic, cardiometabolic and safety outcomes when added to metformin. Methods: Following PRISMA guidelines, PubMed, Embase, Cochrane, Scopus and ClinicalTrials.gov were searched from inception to September 2025. Randomized trials and observational studies comparing empagliflozin + metformin versus sitagliptin + metformin in adults with T2DM were included. Primary outcomes were changes in HbA1c, body weight, fasting glucose, lipid profile and blood pressure. Safety outcomes included urinary tract infections, genital infections, gastrointestinal disturbances and rash. Risk of bias was assessed using RoB 2.0 and the Newcastle–Ottawa Scale. Random‐effects models were used for meta‐analyses, and meta‐regression explored the impact of empagliflozin dose. Results: Eleven studies met eligibility criteria. Empagliflozin produced greater reductions in HbA1c, body weight, fasting glucose and systolic blood pressure compared with sitagliptin. Lipid changes were modest and inconsistent. Rates of urinary infections, gastrointestinal symptoms and rash were comparable between groups, whereas genital infections were significantly higher with empagliflozin. Rare but serious adverse events associated with SGLT2 inhibitors, including Fournier's gangrene and lower limb amputations, were not reported in the included trials. Meta‐regression showed no meaningful dose–response relationship for glycaemic or weight outcomes. Conclusions: In patients with T2DM on metformin, empagliflozin offers superior glycaemic and cardiometabolic benefits compared with sitagliptin, with an increase in genital infections. Both therapies are well tolerated, supporting empagliflozin as an effective metabolic add‐on option. Trial Registration: PROSPERO ID: CRD420251152360Keywords
This publication has 26 references indexed in Scilit:
- Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta‐analysisDiabetes/Metabolism Research and Reviews, 2016
- Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysisEuropean Journal of Clinical Pharmacology, 2016
- Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetesJournal Of Hypertension, 2016
- Effects of Sitagliptin on Lipid Profiles in Patients With Type 2 Diabetes MellitusMedicine, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2015
- The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?Journal of Diabetes Research, 2015
- Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and MetforminDiabetes Care, 2013
- Drugs affecting HbA1c levelsIndian Journal of Endocrinology and Metabolism, 2012
- Bias in meta-analysis detected by a simple, graphical testBMJ, 1997